A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients

Clinical trial NCT04736394 · UNKNOWN

Trial details

NCT number: NCT04736394
Sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Non-muscle Invasive Bladder Cancer

Start date: 2021-09-29
Primary completion: 2025-03-01
Enrollment: 800

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.